Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
0(0%)
Results Posted
60%(3 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
4
50%
Ph phase_3
4
50%

Phase Distribution

4

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
4(50.0%)
Phase 3Large-scale testing
4(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(2)
Other(1)

Detailed Status

Completed5
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (50.0%)
Phase 34 (50.0%)

Trials by Status

terminated225%
completed563%
unknown113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

NCT02753127
completedphase_3

A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

NCT02993731
terminatedphase_3

A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer

NCT02826161
completedphase_1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers

NCT03411122
completedphase_1

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

NCT04299880
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02753127Phase 3

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Completed
NCT02993731Phase 3

A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Completed
NCT02826161Phase 3

A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer

Terminated
NCT03411122Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers

Completed
NCT04299880Phase 1

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Completed
NCT03525405Phase 1

A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

Completed
NCT02851004Phase 1

Special Combination of BBI608 and Pembrolizumab

Terminated
NCT03522649Phase 3

A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8